CA-DIALPAD
16.12.2021 15:02:04 CET | Business Wire | Press release
Dialpad Inc. , the industry leader in AI-powered cloud communications and collaboration, today announced $170 million in funding. The amount raised and valuation of $2.2 billion reflects the increasing importance of a truly unified approach to business communications. To date, Dialpad has raised $418 million in capital.
ICONIQ Capital leads the funding round which includes participation from Amasia, GV, OMERS Growth Equity, Work-Bench, Section 32, and T-Mobile Ventures. Dialpad will use this funding to invest in the further development and application of native artificial intelligence (AI) throughout its unified platform; hiring top talent across data engineering, natural language processing, machine learning and customer-facing roles to support its rapid global growth.
“Dialpad is the world’s most advanced AI-powered communications, collaboration, and contact center platform, providing a customer- and cloud-first solution that enables more efficient and effective conversations,” said Craig Walker, founder and CEO, Dialpad. “This latest round of funding, and increased valuation, showcases Dialpad’s continued momentum and strengthens our dedication to helping companies scale and enterprises thrive in today’s hybrid, work-from-anywhere world.”
“Dialpad is at the forefront of cloud-based, native AI communications, collaboration, and contact center solutions. ICONIQ Capital is proud to again invest in Dialpad’s vision to deliver streamlined communications combined with crucial data-driven insights all through one application,” said Will Griffith, Founding Partner, ICONIQ Capital. “As the creator of Google Voice, Craig Walker knows what it means to disrupt an entire category. Walker recognized the pain points consumers had communicating at scale in the cloud. Now, he is applying that same philosophy with Dialpad, extending it to the enterprise and is once again disrupting the status quo.”
Dialpad is the one place for truly unified Communications as a Service (TrueCaaS™), offering companies and employees the ability to work smarter — not harder — from anywhere on any device. In today’s distributed world, teams need one seamless solution for productive collaboration that also avoids the growing phenomenon of “app overload”. Simple to deploy and backed up with Voice Intelligence (Vi™) to create a searchable archive of every call, Dialpad delivers all modes of business communications through a single pane of glass.
“Customer adoption of Dialpad’s AI-powered TrueCaaS platform is at an all time high and is accelerating,” said Mike Kourey, Chief Financial Officer, Dialpad. “This $170 million financing round further fuels our unparalleled innovation engine and global expansion, advancing Dialpad’s comprehensive vision for the future of work, business communications and collaboration, and customer experience.”
The funding round is the latest development in a year of significant milestones for Dialpad including growth, global expansion, partnerships and acquisitions.
- C-suite expansion to include chief officers for finance , marketing and human resources , technology and operations
- 50% headcount increase year-over-year to nearly 1,000 employees with expanded operations into Australia , New Zealand , Japan, and EMEA
- Acquisitions of Kare Knowledgeware and Koopid to elevate the customer and agent experience with digital self-service, conversational AI, and intelligent omnichannel support
- Partnerships with T-Mobile for Business to enhance work-from-anywhere collaboration
- More than two billion minutes of data analyzed establishing Dialpad Vi transcription model as most accurate in business communications industry
- Recognized as a Major Player in the 2021 IDC MarketScape , included in the Gartner Magic Quadrant for third consecutive year, the 2021 Contact Center Buyers Guide from Frost & Sullivan, and named a leader in the 2021 SPARK Matrix and multiple G2 categories
- Multi-year jersey patch sponsorship and official communications provider with the Sacramento Kings of the NBA which includes notable philanthropic initiatives
Additional Resources
- Read more about Dialpad’s acquisitions of Kare and Koopid
- Learn how Dialpad’s growing partner ecosystem is improving customer experiences
- For more information on Dialpad’s recent CFO appointment , see the press release
Social Networks:
- Web: https://www.dialpad.com/
- Blog: https://www.dialpad.com/blog/
- Twitter: https://twitter.com/dialpadHQ/
- LinkedIn: https://www.linkedin.com/company/dialpad/
- Facebook: https://www.facebook.com/DialpadHQ/
- Instagram: https://www.instagram.com/DialpadHQ/
About Dialpad
Dialpad is the global leader in AI communications for business, transforming how the world works together. Dialpad customers benefit from truly unified business and customer communications, including a cloud business phone system, text and team messaging, video meetings, and the world’s most advanced AI-powered contact center — all in one beautiful app. More than 7,000 innovative brands and millions of people use Dialpad to connect their teams from anywhere including Motorola Solutions, Netflix, T-Mobile, Uber and WeWork. Visit www.dialpad.com for more information and to request a demo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005248/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
